TA Associates’ Post

At Cavendish, we believe AIM is a great platform for owners of businesses as it allows them to source additional capital whilst maintaining an element of control.  It also allows the flexibility for the founders to sell down their stakes in a controlled manner.     Cavendish has been involved in managing multiple sell downs over recent years and completed two in life sciences in last month, realising £11m in aggregate, both at a discount of less than 5% to the mid price.   This is despite ongoing challenges in equity markets.  These two sell downs, in Bioventix (£2.4m) and hVIVO (£8.4m) were both oversubscribed and allowed us to introduce a number of high quality investors to the register.       Geoff Nash, Corporate Finance Director commented: “We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £260m) and started working with hVIVO (then Open Orphan) in mid-2020 when the market capitalisation was £70m (£180m today). If we can help your business, please do get in touch.” #lifesciences #healthcare #growthbusiness #capitalmarkets #AIM

Two great examples of our clients’ continued growth stories on AIM and how recent sell downs have broadened the shareholder base for these firms. #growthbusiness #capitalmarkets #ukeconomy

Exciting News!🚀 Monitra Healthcare Private Limited backed by Equanimity Ventures and Kotak Alternate Asset Managers Limited secures a transformative USD 1.5mn in Pre-Series A funding. Their pioneering upBeat®️ platform is set to redefine cardiac monitoring globally. We’re proud to support advancements of our portfolio company Monitra Healthcare Private Limited in healthcare sector! #EquanimityInvestments #Kotak #MonitraHealth #HealthCare #HealthInnovation #Investments #Funding

Delighted to announce our Gold Partner, NovaQuest Capital Management at our upcoming #ALTSLA in Los Angeles on March 18 & 20, 2024. NovaQuest Capital Management is a specialist life sciences investment firm founded in 2010 by a team of accomplished in-dustry professionals. NovaQuest pioneered a PRODUCT FINANCEcapital solution for the industry, providing shared-risk, non-dilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, and license and acquire accretive products. NovaQuest makes unlevered investments, generally through self-liquidating structures, yielding return streams uncorrelated to broad equity and fixed income markets. With more than $2.5 billion raised across four funds, NovaQuest main-tains investment platforms in human and animal health verticals.    For more information on the event, please visit https://altsla.com/    #CFA, #CAIAAssociation, #CalALTS, #ALTSLA, #ALTSLA24 #MarketsGroup #alternativeinvestments Kareen Mozes Laton Patrick Jordan Michael Bologna Paul Hamann Debra Haym

The Indian IPO market has been experiencing significant activity, drawing widespread attention. Excitement and anticipation are palpable among investors. #IndianIPOs #MarketBuzz Industries like infrastructure, fintech, e-commerce, and pharma are at the forefront of this surge. These sectors are promising substantial growth and innovation. #IndustryLeaders #EconomicGrowth Participation by global investors, including both individuals and corporations, is being actively encouraged. This inclusive approach is opening new doors for international collaboration. #GlobalInvesting #InclusiveGrowth

Exciting Times in Biotech! 🧬 Neumora and RayzeBio are both diving into the IPO waters this fall, aiming to raise over $200 million each. 🚀 Neumora is offering 14,710,000 shares in the range of $16 to $18 apiece, potentially raising a whopping $250 million at the midpoint. 🔬📈 RayzeBio, on the other hand, is planning to make waves with 13,235,000 shares also in the $16 to $18 range, targeting around $225 million at the midpoint. 🌊🔍 Neumora, backed by Amgen and Arch Venture Partners, is on a mission to discover groundbreaking treatments for brain diseases, and they've got a valuation in mind of up to $2.74 billion! 🧠💊 RayzeBio is bringing its radiopharmaceuticals pipeline to the stage, with its lead program, RYZ101, in phase 3 development for gastroenteropancreatic neuroendocrine tumors. 🏥📊 These bold moves reflect a reawakening in the IPO market for biotechs, suggesting a renewed appetite for innovation. #ipo #ipoalert #news #opportunity #healthcare #biotech #innovation #investing Learn more: https://lnkd.in/dnHEk6uD

Sidetrade discussed in detail the highly promising acquisition of SHS Viveon. This deal once again confirms Sidetrade's ability to seize M&A opportunities likely to boost its organic growth potential at prices far removed from market standards. #SidetradeALeader

Professionals involved in the realm of M&A and deal making are undoubtedly acquainted with the prominent names of Ansarada and Datasite. These platforms serve as indispensable tools within the deal space, enabling a level of information sharing that is impeccably smooth and seamlessly efficient. Datasite has now entered into a scheme implementation deed for the acquisition of 100% of Ansarada Group for $2.50 cash per share by way of a scheme of arrangement, implying an equity value of $236.3 million. (Subject to regulatory clearances and relevant approvals). As a deal professional working and living in Australia, I am extremely proud to see an Australian technology company that have scaled up significantly over the years and have revolutionised M&A deal making, being acquired by a private equity backed company. #mergersandacquisitions #deals

The right to health is a basic human right 🏥 On #WorldHealthDay, Amolyt Pharma, with backing from Sofinnova Partners, offers hope to patients worldwide suffering from rare endocrine and related diseases. 💫 €212m raised from VCs 💫 Expansion to 50 employees 💫 $1.05bn acquisition agreement with AstraZeneca With support from investors: Intermediate Capital Group (ICG), Tekla Capital Management, CTI Life Sciences Fund, Andera Partners, Novo Ventures, Kurma Partners, EQT Life Sciences, @Innobio 2 (Bpifrance Investissement), Sectoral Asset Management, Pontifax Venture Capital, OrbiMed, Mass General Brigham Ventures, ATEM, Crédit Agricole Création and Relyens Innovation Santé / Turenne Groupe. Read the full story, and take a look at how investment supports Europe’s most innovative healthcare and life sciences businesses ➡️ https://lnkd.in/emQzXubz #PrivateEquity #VentureCapital #SuccessStories #BuildingBetterBusinesses #pharma #healthcare

➖ CAPITAL RAISE ➖   Adherium has announced a $8.37 million capital raising via a Placement and Non-Renounceable Entitlement Offer.    The Company has received firm commitments for a capital raising of up to $1.57 million before costs, by way of a placement of new shares to sophisticated and professional investors. The placement will be undertaken in two tranches with the second tranche including CEO and Director participation.    Adherium also proposes to undertake a fully underwritten non-renounceable entitlement offer of new shares and new options to eligible shareholders to raise up to $6.8 million before costs.    These funds will be used to fast track US commercialisation of Adherium’s Hailie® Smartinhaler® technology – with multiple FDA clearances and US reimbursement codes now in place.    Adherium CEO, Dr. Paul Mastoridis, said:     “Adherium is entering a defining phase in its commercial development. We are extending the reach and impact of our world-class respiratory health product portfolio within the US, the largest healthcare market in the world. Our Company has a clear and focused US engagement and market penetration strategy, which prioritises manufacturing activities and sales via established pharmaceutical and payor groups in this market.”    For more information, read the ASX release 👉 https://lnkd.in/gs-8BXZX      $ADR #ADR #Adherium #digitalhealth #ehealth #innovation #invest #capitalraise